Sotac Pharmaceuticals Fair Value
Fair Value Analysis Export
P/E Based Valuation
P/B Based Valuation
Asset-Based Valuation
Benjamin Graham Number
SOTAC Fair Value Analysis — Data Sources & Coverage
Sotac Pharmaceuticals financial data sources, valuation methods applied and sector benchmarks used — 2024 financial year. Read SOTAC dividend history for the complete payout history and dividend yield track record.
Available Data Sources: Financial statements, balance sheet data , sector comparisons.
Data Currency: Financial data is 2 years old (2024).
SOTAC vs Healthcare Sector Peers — P/E, P/B & Market Cap
Sotac Pharmaceuticals P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Aurobindo Pharma | AUROPHARMA | 25.88 | 2.53 | ₹96,652 |
| Emcure Pharmaceuticals | EMCURE | 36.8 | 7.52 | ₹37,799 |
| Sat Kartar Life | SATKARTAR | 13.37 | 3.34 | ₹226 |
| Syngene International | SYNGENE | 69.95 | 3.2 | ₹15,307 |
| Divis Laboratories | DIVISLAB | 85.36 | 14.9 | ₹247,470 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.